Blood DNA test in newly diagnosed mediastinal large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how “circulating tumor DNA” in blood changes in people with newly diagnosed primary mediastinal large B-cell lymphoma. It may help doctors better monitor treatment response alongside standard PET/CT-guided care, which could improve follow-up decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your lymphoma is a newly diagnosed primary mediastinal large B-cell type confirmed by biopsy
- You have mediastinal involvement (the lymph cancer is in the chest area/mediastinum)
- You have not started chemotherapy yet (except brief emergency steroid use under certain limits)
- Your pre-treatment PET/CT shows enough activity in the mediastinum (Deauville score 4 or higher)
- You can have FDG PET/CT and can understand and follow study steps (consent required)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial is for people with newly diagnosed DLBCL who have a specific blood marker before treatment and achieve complete remission after standard chemotherapy. The study uses a blood test to help guide whether additional treatment is needed after chemotherapy.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This study tests whether using PET scans and a simple blood test (called liquid biopsy) can quickly and accurately monitor how well your lymphoma is responding to standard first-line treatment. The goal is to see if these real-time monitoring tools can improve care for aggressive B-cell lymphomas.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
Hear when a new Primary Mediastinal Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.